(a) Based on available outcome data which does not include matched cancer incidence data for 2023; therefore confirmed cancers reported here are an underestimate. Percentages may not sum to 100% due to rounding. Excludes 47,738 assessments with no record of outcome.
Notes:
- The recruitment indicator PI 1 is reported against the 2-year calendar period 2022–2023, with follow-up to June 2024. The screening indicator PI 2 is reported against the year 2023. The assessment and adverse events indicators are reported against the year 2023, with follow-up to December 2024 for assessments and to June 2024 for adverse events. Incidence and mortality are estimated age-standardised rates for those aged 50–74 in 2024.
- Assessment, diagnosis and outcomes (PIs 3–9) rely on information being reported back to the NCSR. As return of NBCSP forms is required (ACSQHC 2020), but not mandated by the NBCSP, there may be incomplete form return and incomplete data. However, Participant follow-up function (PFUF) data are now used to supplement missing colonoscopy form data. See Current reporting limitations for more details.
- PI 5a (adenoma detection rate), PI 5b (PPV of diagnostic assessment for detecting adenoma), PI 6a (bowel cancer detection rate), PI 6b (PPV of diagnostic assessment for detecting bowel cancer), PI 7 (interval cancer rate), and PI 8 (cancer clinico-pathological stage distribution) are not reported due to data incompleteness or unavailability. See Current reporting limitations.
Source: AIHW analysis of NCSR as at 31 December 2024 (NCSR raw data extract (RDE]) 13/01/2025).Current reporting limitations
